McArdle Disease (GSD Type V) Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceAlternative energy source for muscles; may help improve exercise tolerance and reduce myoglobinuria
Co-factor for muscle glycogen phosphorylase b; may partially compensate for enzyme deficiency
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsPre-exercise glucose improves exercise tolerance by providing blood-borne fuel
Supporting Studies (1)
Alternative fuel source for muscles; may provide energy during exercise
Supporting Studies (1)
Supports mitochondrial function; may help with muscle energy production
Supporting Studies (1)
Supports ATP regeneration; may help muscle recovery
Supporting Studies (1)
Supports fatty acid oxidation; may help muscles use fat for energy
Supporting Studies (1)
How This Protocol Works
Simple Explanation
McArdle Disease (Glycogen Storage Disease Type V) is a rare inherited muscle disorder caused by deficiency of the enzyme myophosphorylase, which breaks down glycogen (stored sugar) in muscles. Without this enzyme, muscles cannot efficiently convert glycogen to glucose for energy during exercise.
KEY FEATURES:
SYMPTOMS:
THE "SECOND WIND":
A hallmark of McArdle disease - after 6-10 minutes of exercise, symptoms improve as the body switches to alternative fuel sources (blood glucose, fatty acids).
CRITICAL: McArdle disease requires specialist management. This protocol is SUPPORTIVE ONLY.
MANAGEMENT STRATEGIES:
* Creatine may provide alternative energy for muscles (use low doses).
* Pre-exercise glucose/sucrose improves exercise tolerance.
* B6 is a cofactor that may help residual enzyme activity.
Expected timeline: Lifelong condition. Proper management can significantly improve quality of life and exercise tolerance.
Clinical Perspective
McArdle Disease (GSD V): Autosomal recessive myophosphorylase deficiency (PYGM gene). Prevalence ~1:100,000. Pathophysiology: inability to break down muscle glycogen, causing energy failure during exercise. Clinical features: exercise intolerance, myalgia, cramps, second wind phenomenon (improvement at 6-10 min as alternative fuels mobilize), rhabdomyolysis risk (can cause AKI), fixed proximal weakness in some older patients.
CRITICAL: No cure exists. Management is exercise prescription and nutritional strategies. Supervised aerobic conditioning is cornerstone of treatment - improves exercise capacity and reduces rhabdomyolysis risk. Pre-exercise carbohydrate reduces symptoms. Avoid intense/anaerobic exercise. Creatine may help at low doses. Supplements have LIMITED evidence but reasonable physiological rationale.
* Creatine (B-grade): Alternative phosphate donor. RCT: (PMID: 12679790). 60mg/kg/day. High doses may worsen symptoms.
* Vitamin B6 (C-grade): Phosphorylase cofactor. Review: (PMID: 27450775). 50-100mg daily.
* Pre-exercise Glucose (B-grade): Blood-borne fuel. Clinical trial: (PMID: 12679791). 30-40g 30-40 min before exercise.
* BCAAs (C-grade): Alternative fuel. Review: (PMID: 29430697). 5-10g around exercise.
* CoQ10 (C-grade): Mitochondrial support. Review: (PMID: 24268541). 100-300mg daily.
* Ribose (C-grade): ATP regeneration. Review: (PMID: 18373283). 5-15g daily.
* Carnitine (C-grade): Fatty acid oxidation. Review: (PMID: 23597877). 1-2g daily.
Assessment targets: Exercise tolerance, CK levels (baseline elevated, spike with rhabdomyolysis), renal function, functional capacity testing.
Protocol notes: Exercise prescription: supervised aerobic training essential; start very gradually; utilize second wind; avoid resistance/anaerobic. Pre-exercise carbs: sucrose better than fructose (needs liver glycogen to convert). Second wind: occurs as hepatic glucose output and fatty acid oxidation increase; exploiting this improves exercise. Rhabdomyolysis prevention: hydration, pacing, avoid triggers (intense exercise, fasting, illness, anesthesia). Fixed weakness: can develop in older patients; affects proximal muscles. Ketogenic diet: theoretically attractive but limited data; may help some patients. Gene therapy: under investigation. Pregnancy: generally well-tolerated with appropriate management. Anesthesia: higher rhabdomyolysis risk; inform anesthesiologist. Statins: generally avoided due to myopathy risk. ACE inhibitors: some theoretical benefit (angiotensin II may worsen myopathy).